ArticleJournal of translational medicine2025
GPD1L as a potential biomarker associated with Treg cell infiltration and lipid metabolism in clear cell renal cell carcinoma.
Article in Journal of translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- A comprehensive plasma-based approach to thromboinflammation in bladder cancer: integrating lipidomics, thrombin generation, and NETosis biomarkers.Journal of translational medicine · 2026Article
- Immune Escape in Renal Cell Carcinoma: Latest Research and Treatment Strategies.International journal of molecular sciences · 2026Review
- Construction and validation of a palmitoylation-related prognostic model for lung adenocarcinoma based on integrated bioinformatics and machine learning.Translational cancer research · 2026Article
- Unveiling membrane transporter proteins-related genes for predicting the prognosis of hepatocellular carcinoma patients.Discover oncology · 2026Article
- Epigenetically-controlled CEBPB regulates kidney cancer tumorigenesis via GPD1L-mediated ether lipid synthesis.Cell death & disease · 2026Article
- UBE2S emerges as a key driver in an NK cell-based prognostic model for clear cell renal cell carcinoma.PloS one · 2026Article
- Methodological concerns regarding the role of GPD1L in Treg infiltration and lipid metabolism in clear cell renal cell carcinoma.Journal of translational medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundClear cell renal cell carcinoma (ccRCC) is a prevalent tumor in the urinary system, presenting a poor prognosis yet being accompanied by a high degree of immune infiltration. Understanding the mechanisms underlying this abnormal infiltration and identifying prognostic biomarkers in this regard is crucial for improving therapeutic outcomes.
methodsThe expression of GPD1L in ccRCC was analyzed using a common database (TCGA). The expression of GPD1L in ccRCC cell lines and tissue samples was verified by western blotting, real time qPCR and immunohistochemistry. The predictive value of GPD1L was evaluated by survival analysis, ROC curve and Cox regression analysis. We used GO, KEGG and gene set enrichment analysis (GSEA) to verify each other. Then the single cell sequencing dataset (GEO) was further analyzed and verified, and the functional phenotype of GPD1L in ccRCC was explored by functional experiments. In addition, the correlation between the expression level of GPD1L and drug resistance of AKT-mTOR pathway was analyzed based on Genomics of Drug Sensitivity in Cancer database (GDSC).
resultsWe identified glycerol-3-phosphate dehydrogenase 1-like (GPD1L) as a tumor suppressor gene in ccRCC, and downregulation of GPD1L may facilitate the adaptive survival of tumor cells via enhanced regulatory T cells (Tregs) infiltration and lipid metabolism reprogramming in ccRCC. Our results suggest that there is a significantly diminished GPD1L in ccRCC patients with poorer survival probability. Mechanically, a significant negative correlation between GPD1L expression and Tregs infiltration, and GPD1L-related metabolic analysis reflected the correlation between Tregs and lipid metabolism. In addition, GPD1L expression levels also influence the malignant phenotype of ccRCC and the drug resistance to AKT and mTOR targeted therapy.
conclusionsTaken together, our results supported GPD1L could be a valuable biomarker for predicting and intervening in ccRCC progression. These insights could shed light on the complex interplay between tumor cell adaptive survival and Treg infiltration, which reflected that the comprehensive and systemic role of GPD1L in ccRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.